The KEYNOTE-811 trial demonstrated that adding pembrolizumab to trastuzumab and chemotherapy significantly improved objective response rates (ORR 74.4% vs 51.9%) in HER2-positive gastric cancer (4). The gene discussed is ERBB2; the disease is gastric cancer.